For the Inventor, By the Inventor

Enter assignee name

Durham, NC, United States of America

Biocryst Pharmaceuticals, Inc.

USPTO Granted Patents = 82

CIPO Patents = 2

EPO Patents = 21

Trademarks = 11

Forward Citations = 873

Loading Chart...

Loading Chart...

49 inventors (with patents filed for the assignee):

Yarlagadda Sudhakara Babu (65 out of 69 patents)

Pravin L Kotian (47 out of 48 patents)

V Satish Kumar (31 out of 31 patents)

4. Minwan Wu (28 out of 28 patents)

5. Weihe Zhang (27 out of 39 patents)

6. Pooran Chand (25 out of 31 patents)

7. Venkat R Chintareddy (22 out of 22 patents)

8. Shanta Bantia (17 out of 21 patents)

9. Yahya El-Kattan (12 out of 12 patents)

10. Krishnan Raman (10 out of 10 patents)

11. John A Montgomery (9 out of 60 patents)

12. Lakshminarayana Vogeti (8 out of 21 patents)

13. Peng-Cheng Lu (7 out of 7 patents)

14. Wei Lv (5 out of 5 patents)

15. Trung Xuan Nguyen (5 out of 5 patents)

Core Competencies:

Pyrrolo Compounds

Plasma Kallikrein Inhibitors

Antiviral Treatments

ALK2 Kinase Inhibitors

Benzofuran Inhibitors

Zika Virus Treatment

Hematologic Cancers

Prodrugs

Viral Polymerase Inhibition

Amidine Derivatives

Benzopyrazole Compounds

Antiviral Nucleoside Analogs

82 patents: Sort by Forward Citations

1. 12503443 - Process-scale synthesis of a plasma kallikrein inhibitor (2025-12-23),

2. 12485109 - Pyrrolo 12.3-dipyrimidine compounds and analogues thereof (2025-12-02),

3. 12344585 - Crystalline salts of a plasma kallikrein inhibitor (2025-07-01),

4. 12162838 - Human plasma kallikrein inhibitors (2024-12-10),

5. 12121503 - Antiviral treatments (2024-10-22),

6. 12116346 - Human plasma kallikrein inhibitors (2024-10-15),

7. 12054492 - Imidazole-containing inhibitors of ALK2 kinase (2024-08-06),

8. 12043610 - Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors (2024-07-23),

9. 11975003 - Methods and compositions for treatment of Zika virus infection (2024-05-07),

10. 11866418 - Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors (2024-01-09),

11. 11807605 - Human plasma kallikrein inhibitors (2023-11-07),

12. 11708347 - Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors (2023-07-25),

13. 11708333 - Human plasma kallikrein inhibitors (2023-07-25),

14. 11708332 - Human plasma kallikrein inhibitors (2023-07-25),

15. 11685721 - Human plasma kallikrein inhibitors (2023-06-27),

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies for rare diseases. With expertise in protein crystallography, BioCryst has developed multiple small molecule drugs targeting areas such as infectious diseases, cancer, and immune disorders. The company is committed to improving the lives of patients suffering from rare diseases through advanced science and drug development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

82 Patents

#14 in Durham, NC

#113 in North Carolina

#4,383 in US

#9,019 in the World

Durham, NC, United States of America

Biocryst Pharmaceuticals, Inc.

Forward Citations = 873

49 inventors:

Yarlagadda Sudhakara Babu (65 out of 69 patents)

Pravin L Kotian (47 out of 48 patents)

V Satish Kumar (31 out of 31 patents)

4. Minwan Wu (28 out of 28 patents)

5. Weihe Zhang (27 out of 39 patents)

Please report any incorrect information to support@idiyas.com

Loading…